XBIOTECH INC.

The FDA has cleared the IND for V‑SPINE (PT064) without a clinical hold, allowing XBiotech to begin the randomized, double‑blind, placebo‑controlled phase II study in the US. 150 participants are planned to receive 400 mg vilamakitug as 16 weekly subcutaneous injections or placebo; the primary endpoint is ASAS40 response at week 16. The study includes a 12‑week open‑label extension in which all participants receive vilamakitug and aims to assess the potential of IL‑1β blockade to treat inadequately controlled axSpA. » Więcej na finanzen.net

XBiotech Inc. said that shareholders at the annual meeting approved all proposals recommended by the board of directors, including the election of five directors and the ratification of Whitley Penn LLP as auditors. Shareholders also approved the executives' performance-based compensation and the 2025 equity incentive plan. Dr. Thomas Kündig and Craig Rademaker were appointed to the board; Kündig will serve on the Compensation Committee and Rademaker on the Audit Committee. » Więcej na de.investing.com

XBiotech has appointed Dr. Thomas Kündig and Craig Rademaker to its board of directors with immediate effect. Dr. Kündig brings extensive experience in immunodermatology and cancer immunotherapy, while Rademaker contributes expertise in finance and capital markets. The appointments are intended to strengthen the leadership structure of the biotechnology company, which is currently facing profitability challenges. » Więcej na de.investing.com